Kim Min Chan, Shin Sangyun, Koh Myeongseok
Department of Surgery, Dong-A University College of Medicine, Busan, Korea.
Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
J Minim Invasive Surg. 2023 Mar 15;26(1):21-27. doi: 10.7602/jmis.2023.26.1.21.
Esophagojejunostomy leakage after total gastrectomy for gastric cancer is one of the most serious and sometimes life-threatening adverse events. The purpose of this study was to evaluate complications after total gastrectomy in patients with gastric cancer during the period when Histoacryl (B. Braun) injection was performed. Therapeutic outcome of endoscopic Histoacryl injection for esophagojejunostomy leakage was also determined.
This was a single-center retrospective study. Between January 2016 and December 2021, clinicopathologic characteristics and surgical outcomes of 205 patients who underwent total gastrectomy were investigated. Baseline characteristics and clinical outcomes of 10 patients with esophagojejunostomy leakage were also investigated.
Postoperative complication and mortality rates of total gastrectomy in 205 patients were 25.4% and 0.9%, respectively. Serious complications more than Clavien-Dindo IIIb accounted for 6.3%. Ten (4.9%) esophagojejunostomy leakages occurred in 205 patients. Among 10 esophagojejunostomy leakage patients, endoscopic Histoacryl injection was performed on eight patients and leakage was successfully managed with endoscopic Histoacryl injection in seven patients (87.5%). Mean postinjection hospital stay of seven successfully managed patients was 13.8 days. They were able to drink water at 1-6 days after injection. Among eight patients with endoscopic Histoacryl injection, six patients were injected once and two patients were injected three times.
Endoscopic Histoacryl injection for esophagojejunostomy leakage after total gastrectomy can be considered as a useful treatment for some selected cases.
胃癌全胃切除术后食管空肠吻合口漏是最严重且有时会危及生命的不良事件之一。本研究的目的是评估在进行组织黏合剂(贝朗公司生产)注射期间,胃癌患者全胃切除术后的并发症情况。同时也确定了内镜下注射组织黏合剂治疗食管空肠吻合口漏的治疗效果。
这是一项单中心回顾性研究。调查了2016年1月至2021年12月期间接受全胃切除术的205例患者的临床病理特征和手术结果。还调查了10例食管空肠吻合口漏患者的基线特征和临床结果。
205例患者全胃切除术后的并发症发生率和死亡率分别为25.4%和0.9%。Clavien-Dindo IIIb级以上的严重并发症占6.3%。205例患者中有10例(4.9%)发生食管空肠吻合口漏。在10例食管空肠吻合口漏患者中,8例接受了内镜下组织黏合剂注射,7例(87.5%)通过内镜下组织黏合剂注射成功控制了漏口。7例成功治疗的患者注射后的平均住院时间为13.8天。他们在注射后1至6天能够饮水。在8例接受内镜下组织黏合剂注射的患者中,6例注射了一次,2例注射了三次。
对于全胃切除术后食管空肠吻合口漏,内镜下注射组织黏合剂可被视为某些特定病例的有效治疗方法。